Mehmet ERDOĞAN, Zuhal EROĞLU, Soner SOLMAZ, Sencer GANİDAGLİ, Aslı TETİK, Abdullah CANATAROĞLU

The Relationship of the Peroxisome Proliferator Activated Receptor-Gamma 2 Exon 2 and Exon 6 Gene Polymorphism in Type 2 Diabetic Patients with and without Diabetic Foot Ulcers

We aims investigate Turkish type 2 diabetic patients with/without diabetic foot ulcers and healthy group and examined the contribution of the Pro12Ala exon 2 and C478T exon 6 of the PPARgamma gene polymorphisms to the development of diabetic foot ulcers. The PPARgamma genotypes were determined prospectively in 50 patients with diabetic foot ulcers and 50 without diabetic foot ulcers and a control group of 50 healthy individuals. Genotyping of the Pro12Ala exon 2 and C478T exon 6 of the PPAR-gamma gene polymorphisms for all individuals was performed by PCR-RFLP method. The genotype exon 2 and exon 6 distribution did not differ between the control group and the type 2 diabetes mellitus patients (with and without diabetic foot) (P>0.05). The frequency of the polymorphic G allele in exon 2 was no similar for the groups (6% and 1%, respectively) (p<0.05). The frequency of the polymorphic T allele in exon 6 was similar for the groups (p>0.05). The evaluation of exon 2 and exon 6, genotype and haplotype did not show statistically significant difference between the patient diabetic foot and without diabetic foot (p>0.05). The Pro12Ala exon 2 and C478T exon 6 of the PPARgamma gene polymorphisms are not an independent risk factor for diabetic foot in Turkish type 2 diabetes mellitus patients. Genetic factors in the pathogenesis of diabetic foot may also show any changes in different populations.

PDF

___

1. Richard JL, Schuldiner S. Epidemiology of diabetic foot problems. Rev Med Interne. 2008;29 Suppl 2:S222-30.

2. Malgrange D. Physiopathology of the diabetic foot. Rev Med Interne. 2008;29 Suppl 2:S231-7.

3. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-14.

4. Martini J. Diabetic foot: detection and prevention. Rev Med Interne. 2008;29 Suppl 2:S260-3.

5. Got I. Peripheral vascular disease and diabetic foot. Rev Med Interne. 2008;29 Suppl 2: S249-59.

6. Ricco JB, Thanh Phong L, Schneider F, Illuminati G, Belmonte R, Valagier A, Régnault De La Mothe G. The diabetic foot: a review. J Cardiovasc Surg (Torino). 2013;54(6):755-62.

7. Senneville E. Infection and diabetic foot. Rev Med Interne. 2008;29 Suppl 2: S243-8.

8. Ray DM, Spinelli SL, O'Brien JJ, Blumberg N, Phipps RP. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs. 2006;20(4):231-41.

9. Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5(5):377-86.

10. Deray G, Izzedine H, Launay-Vacher V, Bagnis C. [Kidney and glitazones] Ann Endocrinol (Paris). 2005;66(2 Pt 2):1S81-90.

11. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension. 2001;37(2 Pt 2):722-7.

12. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Pilarska K. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res. 2006;37(6):736-43.

13. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A Comparison of Two Diabetic Foot Ulcer Classification Systems: The Wagner and The University of Texas Wound Classification Systems. Diabetes Care. 2001;24(1):84-8.

14. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, van Baal J, van Merode F, Schaper N. High Prevalence of Ischemia, Infection and Serious Comorbidity in Patients with Diabetic Foot Disease in Europe. Diabetologia. 2007;50(1):18-25.

15. Tan KC, O K, Chow WS, Ai VH, Siow YL, Lam KS. Hyperhomocysteinemia and Impaired vasomotor Function in Type 2 Diabetes Mellitus. Eur J Clin Invest. 2002;32(5):328-34.

16. Buysschaert M, Jamart J, Dramais AS, Wallemacq P, Hermans MP. Micro- and Macrovascular Complications and Hyperhomocysteinemia in Type 1 Diabetic Patients. Diabetes Metab. 2001;27(6):655-9.

17. Leese GP, Feng Z, Leese RM, Dibben C, Emslie-Smith A. Impact of health-care accessibility and social deprivation on diabetes related foot disease. Diabet Med. 2013;30(4):484-90.

18. Mansoor Q, Javaid A, Bilal N, Ismail M. Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus. J Diabetes. 2012;4(3):257-61.

19. Jurado J, Ybarra J, Romeo JH, Garcia M, Zabaleta-Del-Olmo E. Angiotensinconverting enzyme gene single polymorphism as a genetic biomarker of diabetic peripheral neuropathy: longitudinal prospective study. J Diabetes Complications. 2012;26(2):77-82.

20. Moleda P, Majkowska L, Safranow K, Adler G, Goracy I. [Relationship between I/D polymorphism of angiotensin I converting enzyme gene and microvascular complications in type 2 diabetic patients]. Przegl Lek. 2007;64(3):134-9.

21. Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-?/? agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.

22. Erdogan M, Karadeniz M, Eroglu Z, Tezcanlı B, Selvib N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract. 2007;78(3):355-9.